Skip to main content

Table 2 Efficacy indicators

From: Efficacy and safety of tetramethylpyrazine phosphate on pulmonary hypertension: study protocol for a randomized controlled study

Main efficacy indicators

Secondary efficacy measurements

6MWD

HRR1

Pulmonary hypertension WHO classification

Borg Dyspnea Score

Minnesota Living with Heart Failure Questionnaire

NT-proBNP

cTNI

RVSP

Uric acid

Volume of pericardial effusion

Pulmonary artery diameter

Diameter of the same layer of aorta

Arterial oxygen saturation

Time of clinical deterioration

  1. Clinical deterioration is defined as the need to increase medication or change the therapeutic regimen for the treatment of PH, particularly inhaled, intravenous, or subcutaneous application of prostacyclin and its analogues; aggravated symptoms of right heart failure that do not respond to diuretics; atrial septostomy or death; lung transplantation; or hospitalization caused by exacerbation of PH
  2. Other clinical symptoms and signs, biochemical indicators, and imaging indicators are recorded (Table 2) for comprehensive prognostic evaluation and risk assessment